Claris Biotherapeutics closed an $118 million Series B and set course for pivotal testing of CSB-001, an ophthalmic solution for limbal stem cell deficiency. The funding supports two pivotal trials planned for initiation in the first half of 2027, as Claris seeks what would be the first pharmacologic therapy for LSCD. The company’s lead candidate, oremepermin alfa (CSB-001), uses recombinant human deleted hepatocyte growth factor to promote corneal epithelial regeneration while modulating inflammation and fibrosis. Claris cited proof-of-concept clinical signals showing meaningful improvement in visual acuity, distinguishing the approach from surgical stem cell transplantation routes. Leadership and board updates accompany the financing, aligning strategic execution with the transition from earlier-stage data toward late-stage regulatory endpoints.